Get an email when this journal's indexing changes
Added to or removed from Scopus, Web of Science, ABDC, DOAJ, FT50, UT Dallas or ONOS. One confirmation click; unsubscribe anytime.
Pharmaceutical Science Advances is Scopus-indexed (Q1, CiteScore 5.9), DOAJ. Published by Elsevier B.V..
Checked against the index lists dated .
ISSN 2773-2169Verify ISSN ↗
Publisher: Elsevier B.V.
Cost to publish: Checking DOAJ for article charges…
| Subject area | Rank | Pctile | Q |
|---|---|---|---|
| Pharmacology, Toxicology and Pharmaceutics (miscellaneous) | 6 / 57 | 90th | Q1 |
| Pharmaceutical Science | 61 / 191 | 68th | Q2 |
| Pharmacology | 105 / 328 | 68th | Q2 |
Not listed in: Web of Science, ABDC, ABS / AJG, FT50, UT Dallas, ONOS (subscription), ONOS (APC covered)
Yes — actively indexed in Scopus, coverage 2023–present, best quartile Q1, CiteScore 5.9.
Pharmaceutical Science Advances is Q1 in Pharmacology, Toxicology and Pharmaceutics (miscellaneous) (rank 6 of 57), Q2 in Pharmaceutical Science (rank 61 of 191) and Q2 in Pharmacology (rank 105 of 328), by CiteScore 2025.
Pharmaceutical Science Advances is not in the Web of Science Core Collection (SCIE, SSCI, AHCI or ESCI), so Clarivate publishes no Journal Impact Factor for it. Its Scopus CiteScore is 5.9, quartile Q1, 90th percentile. Any "impact factor" quoted elsewhere is not the Clarivate metric. Its SCImago Journal Rank (SJR, a free Scopus-based metric) is 1.084, quartile Q1, with an H-index of 12.
The publisher lists an article processing charge of about US$2,000 for open access (source: OpenAlex). Many journals also publish by the subscription route at no cost to the author, so confirm on the journal's own website.
Pharmaceutical Science Advances is published by Elsevier B.V. Its ISSN is 2773-2169.
No — it is not currently in the Web of Science core collections (SCIE, SSCI, AHCI or ESCI).
Yes — it is an open-access journal, listed in DOAJ.
Pharmaceutical Science Advances has an h-index of 18 and a 2-year mean of 6.25 citations per paper (OpenAlex). Its Scopus CiteScore is 5.9, quartile Q1. On 2-year citations it ranks #3 of 52 Scopus journals in Pharmacology, Toxicology and Pharmaceutics (miscellaneous).
Pharmaceutical Science Advances published 40 papers in 2025. 2026* is the year so far.
h-index, i10-index and 2-year mean citedness are open, licence-clear metrics from OpenAlex — not a proprietary impact factor. The subject rank counts only journals that OpenAlex has a figure for; it is not a Scopus or Clarivate ranking. Updated 2026-10-14.
In its latest 97 research articles (2023–2026), authors are most often from China (63.7%), India (5.7%) and Nigeria (5.3%). More than half of recent authorship comes from one country.
Countries are counted fractionally, so a paper by authors from two countries counts half to each.
Scopus status: Active. No retracted papers are recorded. The Problematic Paper Screener flags none of its papers. These are indicators to check, not findings against the journal.
Retractions from OpenAlex; flags from the Problematic Paper Screener (Cabanac, Labbé & Magazinov, CC BY), 2026-09-21 export. A flag marks a paper for a closer look; it is not a finding against the journal.
Index data is curated from public sources (Scopus, Web of Science, ABDC, FT50, UT Dallas, DOAJ). CiteScore and quartiles reflect the latest available Scopus release. Always verify a journal's current status on its official source before submitting.
Comments load as you scroll here.